// App-Quantinova.ai

SAT0138 : DRUG-RELATED PANCYTOPENIA AND LEUKOPENIA IN RHEUMATOID ARTHRITIS: ARE ALL CSDMARDS EQUAL?

Researchers

Presenter

  • L. Carmona

Principal Investigators

  • J. Weaver

  • E. Burn

  • B. Illingens

  • D. Vizcaya

  • R. Sawant

  • T. Duarte-Salles

  • P. Ryan

  • D. Prieto-Alhambra

Medical Centers

  • InMusc, Madrid, Spain

  • Janssen Research and Development, Titusville, New Jersey, United States of America

  • University of Oxford, Oxford, United Kingdom

  • Harvard Medical School, Beth Israel Deaconess Medical Center - Department of Medicine, Boston, United States of America

  • Epidemiology, Bayer, Barcelona, Spain

  • Idiap Jordi Gol, UAB, Barcelona, Spain

Locations

  • Spain

  • United States

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Autoimmune (AI)

Disease

  • Inflammatory Arthritis

  • Rheumatoid arthritis

Biomarkers

  • Breakpoint Cluster Region

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • Novartis

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved